In a report published Wednesday, analysts at Morgan Stanley maintain their Equal-Weight rating on Johnson & Johnson JNJ. The company reported its 1Q results, with Devices largely in line with the estimates and the Pharma segment beating the consensus.
The company growth trajectory is still the source of speculation, given its 1Q results. The analysts said that most of the upside, relative to the consensus, was driven by Pharma. The company has revised its EPS guidance down, in line with the estimates.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in